Fig. 4: Gemcitabine is well tolerated by Fancg−/− mice with a transient effect on bone marrow cellularity.
From: Gemcitabine as chemotherapy of head and neck cancer in Fanconi anemia patients
A–C Representative H&E sections of the spleen (A), small intestine (SI) (B), and bone marrow (BM) (sternum) (C) isolated from Fancg−/− mice treated with PBS, 120 mg/kg gemcitabine or low dose 0.8 mg/kg cisplatin and harvested on day 2 post-treatment. Red arrows indicate apoptotic cells. D Representative H&E sections of BM (sternum) isolated from Fancg−/− mice treated with PBS, 120 mg/kg gemcitabine, or 0.8 mg/kg cisplatin and harvested on day 7 post-treatment.
